Dutasteride NEW

Dutasteride is a second generation α5 reductase inhibitor approved in the United States for the treatment of benign prostatic hyperplasia. Dutasteride inhibits the conversion of testosterone to dihydrotestosterone, which is an important component in the formation and maintenance of prostate hyperplasia. DHT levels decreased during dutasteride treatment, but serum testosterone levels remained unchanged. Unlike alpha1 adrenoceptor antagonists, which work immediately, dutasteride takes several months to work on prostate size and symptoms of prostatic hyperplasia (urination hesitationand poor urination).

Drug interaction

Dutasteride is metabolized by CYP3A4 in the liver, and in vitro studies have shown that CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, diltiazide, cimetidine, and ciprofloxacin increase plasma moderate tasteride concentrations without pharmacological or pharmacokinetic interactions with tamoxine, terazosin, warfarin, and coletenide.

Application:

Dutasteride is a 5α-reductase inhibitor.